A common eye condition known as dry eye syndrome is characterized by insufficient tear production or rapid tear evaporation, causing dryness, irritation, and pain. A common etiological cause for dry eye disease (DED) that affects both the composition and production of tears is meibomian gland dysfunction (MGD). Meibum, an oily substance produced by the meibomian glands, is essential for preventing tear evaporation. The temporary alleviation offered by standard dry eye therapies has prompted researchers to investigate new therapeutic modalities. Platelet-rich plasma (PRP) therapy has been identified as a viable approach for stimulating meibomian gland activity and improving tear production in dry eye patients. Highly concentrated platelets and growth factors found in PRP are essential for promoting tissue regeneration and accelerating the healing process. By the application or injection of PRP in the affected region, the growth factors could stimulate the production and release of meibum, thereby improving the functionality of the meibomian glands and reinstating the stability of the tear film. The objective of this review article is to conduct a comprehensive analysis of clinical evidence supporting the utilization of PRP therapy in managing MGD and dry eye syndrome. Several studies have demonstrated the efficacy of PRP therapy in enhancing meibomian gland function, mitigating ocular surface inflammation, and alleviating symptoms associated with dry eye. Based on the research outcomes, it has been determined that PRP therapy exhibits potential efficacy as a novel intervention for treating dry eye syndrome. This therapeutic approach demonstrates the ability to enhance the health of the ocular surface and target the fundamental etiological factors associated with this condition. Additional research and investigation are required to ascertain the optimal protocols and long-term efficacy of PRP therapy in treating dry eye and MGD. In conclusion, PRP therapy represents a promising and effective treatment option for patients suffering from dry eye syndrome and MGD, offering significant improvements in ocular surface health and patient quality of life.